abc27

Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
New Atlas

Non-surgical treatment eases chronic back pain & restores function

A clinical trial on the VIA Disc NP treatment for discogenic back pain has shown impressive results, significantly reducing pain and improving back function. The non-surgical, minimally invasive ...
Yahoo Finance

Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease

MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.
WKRG

Data readout expected in Q1 2026

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND ...